92.97
0.82 (0.89%)
| Previous Close | 92.15 |
| Open | 92.02 |
| Volume | 536,880 |
| Avg. Volume (3M) | 621,245 |
| Market Cap | 5,505,600,000 |
| Price / Earnings (TTM) | 47.19 |
| Price / Earnings (Forward) | 21.79 |
| Price / Sales | 3.61 |
| Price / Book | 3.40 |
| 52 Weeks Range | |
| Earnings Date | 30 Oct 2025 |
| Profit Margin | 8.81% |
| Operating Margin (TTM) | 11.83% |
| Diluted EPS (TTM) | 2.04 |
| Quarterly Revenue Growth (YOY) | 9.80% |
| Quarterly Earnings Growth (YOY) | 6.80% |
| Total Debt/Equity (MRQ) | 57.24% |
| Current Ratio (MRQ) | 4.87 |
| Operating Cash Flow (TTM) | 225.16 M |
| Levered Free Cash Flow (TTM) | 172.75 M |
| Return on Assets (TTM) | 4.32% |
| Return on Equity (TTM) | 9.16% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Medical Instruments & Supplies (US) | Mixed | Bearish |
| Medical Instruments & Supplies (Global) | Mixed | Bearish | |
| Stock | Merit Medical Systems, Inc. | Bearish | Bearish |
AIStockmoo Score
| Analyst Consensus | 2.0 |
| Insider Activity | NA |
| Price Volatility | 2.0 |
| Technical Moving Averages | -2.5 |
| Technical Oscillators | 0.5 |
| Average | 0.50 |
|
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment which consists of cardiology and radiology medical device products that assist in diagnosing and treating coronary artery disease, peripheral vascular disease, and other non-vascular diseases and includes embolotherapeutic, cardiac rhythm management, electrophysiology, critical care, and interventional oncology and spine devices. |
|
| Sector | Healthcare |
| Industry | Medical Instruments & Supplies |
| Investment Style | Small Growth |
| % Held by Insiders | 2.23% |
| % Held by Institutions | 109.41% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 108.00 (Needham, 16.17%) | Buy |
| Median | 103.00 (10.79%) | |
| Low | 100.00 (Wells Fargo, 7.56%) | Buy |
| Average | 103.60 (11.43%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 84.49 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Barrington Research | 31 Jul 2025 | 103.00 (10.79%) | Buy | 84.86 |
| Piper Sandler | 31 Jul 2025 | 105.00 (12.94%) | Buy | 84.86 |
| Raymond James | 31 Jul 2025 | 102.00 (9.71%) | Buy | 84.86 |
| Wells Fargo | 31 Jul 2025 | 100.00 (7.56%) | Buy | 84.86 |
| Needham | 18 Jul 2025 | 108.00 (16.17%) | Buy | 83.02 |
| 08 Jul 2025 | 108.00 (16.17%) | Buy | 95.34 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 12 Sep 2025 | Announcement | Merit Medical Embosphere Microspheres Achieve CE Mark for Genicular Artery Embolisation to Treat Knee Osteoarthritis |
| 18 Aug 2025 | Announcement | First Patient Enrolled in Merit Medical’s WRAPSODY (WRAP) North America Registry |
| 07 Aug 2025 | Announcement | Merit Medical Launches the Prelude Wave Hydrophilic Sheath Introducer with SnapFix Technology |
| 30 Jul 2025 | Announcement | Merit Medical Reports Second Quarter 2025 Results and Updates Full-Year Guidance |
| 07 Jul 2025 | Announcement | Merit Medical Names Martha Aronson as New President and Chief Executive Officer |
| 03 Jul 2025 | Announcement | Merit Medical Systems To Announce Second Quarter 2025 Results On July 30, 2025 |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |